Collectively, these findings suggest that inhibiting mutant FAT1 reduces CPT1A levels by downregulating the AKT‐ASCL2 signaling axis, thereby reducing FAO and leading to LDs and ROS accumulation in HNSCC cells (Figure7). This evidence concerns the gene FAT1 and head and neck squamous cell carcinoma.